BamSEC and AlphaSense Join Forces
Learn More

Cidara Therapeutics Inc.

NASDAQ: CDTX    
Share price (12/20/24): $23.22    
Market cap (12/20/24): $254 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 30 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 54 pages Securities Purchase Agreement
12/34/56
EX-10.4
from 10-Q 55 pages License and Technology Transfer Agreement Between Cidara Therapeutics, Inc. and Janssen Pharmaceuticals, Inc. April 23, 2024
12/34/56
EX-10.3
from 10-Q 26 pages Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan Adopted by the Board of Directors: December 4, 2020 Amended by the Compensation Committee of the Board of Directors: August 16, 2021 Amended by the Compensation and Human Capital Committee of the Board of Directors: July 18, 2024
12/34/56
EX-10.1
from 8-K 49 pages Cidara Therapeutics, Inc. 2024 Equity Incentive Plan Adopted by the Board of Directors: May 22, 2024 Approved by the Stockholders: July 18, 2024
12/34/56
EX-10.2
from 8-K 5 pages Support Agreement
12/34/56
EX-10.1
from 8-K 61 pages Securities Purchase Agreement
12/34/56
EX-10.5
from 10-K 2 pages Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 4, 2023
12/34/56
EX-10.1
from 10-Q 1 page Seventh Amendment to Lease Dated April 20, 2023
12/34/56
EX-10.5
from 10-K 2 pages Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 5, 2022
12/34/56
EX-10.4
from 10-Q 8 pages August 19, 2021 by Email Re: Employment Agreement Dear Preetam
12/34/56
EX-10.3
from 10-Q 8 pages August 17, 2021 by Email
12/34/56
EX-10.2
from 10-Q 8 pages March 22, 2017 by Hand Delivery and Email Taylor Sandison Re: Employment Agreement Dear Taylor
12/34/56
EX-10.1
from 10-Q 56 pages License Agreement
12/34/56
EX-10.2
from 10-Q 6 pages Certain Confidential Portions Have Been Redacted From This Exhibit Because They Are Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Has Been Omitted Has Been Identified in This Document With a Placeholder Identified by the Mark “[***]”. 1.the Prepayment
12/34/56
EX-10.26
from 10-K 1 page Fifth Amendment to Lease Dated January 13, 2020
12/34/56
EX-10.5
from 10-K 2 pages Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 13, 2021
12/34/56
EX-10.3
from 10-Q 1 page Sixth Amendment to Lease
12/34/56
EX-10.2
from 10-Q 13 pages , [Date] by Email [See Schedule I: “Executive Officer”] 6310 Nancy Ridge Drive, Suite 101 San Diego, Ca 92121 Re: Amended & Restated Employment Agreement1 Dear [See Schedule I: “Executive Officer”]
12/34/56
EX-10.3
from 10-Q 2 pages Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: March 17, 2021
12/34/56